e-ISSN: Pending
Failed Experiment ReportOpen accessImmunology and Microbiology· cited by 27

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC)

Carl Christoph Schimanski; Stefan Kasper; Susanna Hegewisch‐Becker; Jan Schröder; Friedrich Overkamp; Frank Kullmann; Wolf O. Bechstein; Matthias Vöhringer · 2020 · OncoImmunology

WASTE classifies this as Failed Experiment Report · AI classification, approximate

An experimental approach did not work as intended — learn what to avoid before investing the same effort.

Abstract (excerpt)

= .2141), respectively. Cox regression models revealed no dependence of RFS or OS on MUC1 expression. The most common tecemotide-related grade 3/4 adverse events were diarrhea, injection site reaction, intestinal perforation, peritonitis…

Excerpt shown for reference under fair use — read the full paper at the publisher.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1080/2162402x.2020.1806680